Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate

Schrantee, A.; Tremoleda, J.L.; Wylezinska-Arridge, M.; Bouet, V.; Hesseling, P.; Meierhoff, G.F.; de Bruin, K.M.; Koeleman, J.; Freret, T.; Boulouard, M.; Desfosses, E.; Galineau, L.; Gozzi, A.; Dauphin, F.; Gsell, W.; Booij, J.; Lucassen, P.J.; Reneman, L.

DOI
10.1371/journal.pone.0172776

Publication date
2017

Document Version
Final published version

Published in
PLoS ONE

License
CC BY

Citation for published version (APA):
Schrantee, A., Tremoleda, J. L., Wylezinska-Arridge, M., Bouet, V., Hesseling, P., Meierhoff, G. F., de Bruin, K. M., Koeleman, J., Freret, T., Boulouard, M., Desfosses, E., Galineau, L., Gozzi, A., Dauphin, F., Gsell, W., Booij, J., Lucassen, P. J., & Reneman, L. (2017). Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate. PLoS ONE, 12(2), Article e0172776. https://doi.org/10.1371/journal.pone.0172776
Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate

Anouk Schrantee1,2,*, Jordi L. Tremoleda2,3, Marzena Wylezinska-Arridge2,4, Valentine Bouet5, Peter Hesseling6, Gideon F. Meerhoff6, Kora M. de Bruin7, Jan Koeleman1, Thomas Freret5, Michel Boulouard5, Emilie Desfosses8, Laurent Galineau8, Alessandro Gozzi9, François Dauphin5, Willy Gsell2,10, Jan Booij7, Paul J. Lucassen5, Liesbeth Reneman1

1 Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 2 Biological Imaging Centre, Imperial College London, White City, London, United Kingdom, 3 Centre for Trauma Sciences, The Blizard Institute, London, United Kingdom, 4 Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, Queen Square, London, United Kingdom, 5 Normandie-Université, GMPc, EA 4259, Université de Caen Basse-Normandie, Caen, France, 6 Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, The Netherlands, 7 Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 8 UMR Inserm U930, Université François-Rabelais de Tours, Tours, France, 9 Functional Neuroimaging Laboratory, Istituto Italiano di Tecnologia, Center for Neuroscience and Cognitive Systems @ UNITN, Rovereto, Italy, 10 Biomedical MRI, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium

* a.g.schrantee@amc.uva.nl

Abstract

Dexamphetamine (AMPH) is a psychostimulant drug that is used both recreationally and as medication for attention deficit hyperactivity disorder. Preclinical studies have demonstrated that repeated exposure to AMPH can induce damage to nerve terminals of dopamine (DA) neurons. We here assessed the underlying neurobiological changes in the DA system following repeated AMPH exposure and pre-treated rats with AMPH or saline (4 times 5 mg/kg s.c., 2 hours apart), followed by a 1-week washout period. We then used pharmacological MRI (phMRI) with a methylphenidate (MPH) challenge, as a sensitive and non-invasive in vivo measure of DAergic function. We subsequently validated the DA-ergic changes post-mortem, using a.o. high-performance liquid chromatography (HPLC) and autoradiography. In the AMPH pre-treated group, we observed a significantly larger BOLD response to the MPH challenge, particularly in DA-ergic brain areas and their downstream projections. Subsequent autoradiography studies showed that AMPH pre-treatment significantly reduced DA transporter (DAT) density in the caudate-putamen (CPu) and nucleus accumbens, whereas HPLC analysis revealed increases in the DA metabolite homovanillic acid in the CPu. Our results suggest that AMPH pre-treatment alters DAergic responsiveness, a change that can be detected with phMRI in rats. These phMRI changes likely reflect increased DA release together with reduced DAT binding. The ability to assess subtle synaptic changes using phMRI is promising for both preclinical studies of drug discovery, and for clinical...
studies where phMRI can be a useful tool to non-invasively investigate DA abnormalities, e.g. in neuropsychiatric disorders.

Introduction

Dexamphetamine (AMPH) is a psychostimulant that is often used, both recreationally and for the treatment of attention deficit hyperactivity disorder (ADHD). Shortly after acute administration, dexamphetamine (AMPH) induces large increases in dopamine (DA) concentrations. However, repeated AMPH treatment may cause lasting reductions in striatal DA, in its major metabolite dihydroxyphenylacetic acid (DOPAC), its rate-limiting enzyme tyrosine hydroxylase, its membrane transporter (DAT) and in the vesicular monoamine transporter (VMAT2) [1–4], not only at high (toxic) doses, but likely also at already much lower doses such as those used to treat ADHD patients [5]. In addition to the reduction in DA-ergic presynaptic markers, repeated intermittent exposure to AMPH can result in an exaggerated DA response [6,7], that is thought to be mediated by increased DA release and/or reductions in DA re-uptake and metabolism [7].

Previous studies have demonstrated the potential of pharmacological MRI (phMRI) as a meaningful tool to visualize DAergic dysfunction [8,9]. PhMRI can measure evoked changes in brain hemodynamics as a result of neurotransmitter-specific drug challenges. Previous studies have demonstrated that phMRI can visualize the effects of DA neurotoxicity, which strongly correlated with measures of the DAT, DA concentrations and behaviour [8,10]. For example, DA neuron loss induced by strong and well-documented DAergic neurotoxins, such as 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) resulted in a blunted phMRI response in animals. More recent preclinical studies have demonstrated that phMRI can also visualize more complex alterations in DA-ergic nerve terminals in animal models of addiction [11] and autism [12]. As phMRI is non-invasive, it could potentially be a powerful tool to investigate effects of AMPH treatment on the DA system of children and adolescents with ADHD. Here, we used phMRI to assess remodelling of the DA synapse in a rodent model of repeated AMPH administration [13], known to induce neurotoxic changes to the DA system, using phMRI. In order to further validate the neurobiological substrates underlying changes in phMRI signal, we assessed DAT as well as DA receptor alterations, DA levels and its metabolites using immunocytochemistry, autoradiography, ex vivo storage phosphor imaging and high-performance liquid chromatography (HPLC) analysis.

Methods

PhMRI was used to assess DA functionality following a DA-ergic challenge with AMPH. In the same rats, immunocytochemistry (ICC) was used afterwards to measure overall DAT and DA receptor levels. In different groups of rats with the same treatment protocol, in vitro autoradiography was used to assess DAT and DA D_1 (DRD1) availability, ex vivo storage phosphor imaging to measure striatal DA D_2/3 receptor (DRD2/3) availability and high-performance liquid chromatography (HPLC) to assess in vivo levels of DA and its metabolites.

Animal procedures and treatment

All experiments were approved by the local animal ethical committee and carried out in strict accordance with European guidelines (EU Directive 2010/63/EU) to minimize animal suffering. The studies were conducted in adult male Sprague Dawley rats (Charles River, UK, Janvier
Labs, France and Harlan, the Netherlands), weighing between 200–300 g. In all experiments, the rats were divided in two groups that received either treatment with AMPH (5 mg/kg s.c. four times 2 hours apart) or with saline (also four times 2 hours apart s.c.), as this dose has been shown to induce damage in the DA synapse [13]. AMPH (Sigma Aldrich) was dissolved in 0.9% saline and injected s.c. in a final volume of 1 ml/kg body weight.

1. For the phMRI and immunohistochemistry, all experiments were carried out in accordance with the Animals Scientific Procedures Act 1986 under a project approved by the United Kingdom Home Office. N = 21 rats were pre-treated with saline and N = 21 were pre-treated with AMPH. Due to the experimental set-up it was not possible to obtain perfused brains for all animals in the phMRI study. Therefore, N = 15 AMPH pre-treated and N = 15 saline pre-treated animals were available for immunohistochemistry. All animals in this group were anaesthetized with isoflurane and sacrificed using either cardiac perfusion or cervical dislocation under anaesthesia.

2. The autoradiography and HPLC experiments were approved by the Comité d’Ethique Normandie en Matière d’Expérimentation Animale. For the autoradiography experiments N = 12 saline pre-treated and N = 12 AMPH pre-treated animals were included, whereas for the HPLC experiments N = 12 saline pre-treated and N = 11 AMPH pre-treated animals were used. All animals were sedated with isoflurane and euthanized by cervical dislocation under anaesthesia.

3. The storage phosphor imaging experiments were approved by the Animal Experiments Committee (DEC) at the Academic Medical Centre Amsterdam. For these experiments rats (N = 10 AMPH pre-treated, N = 10 saline pre-treated) were anesthetized with ketamine/xylazine mix and sacrificed using cardiac puncture under anaesthesia.

**phMRI for DA functionality**

The phMRI experiments were carried out following a washout period of 7 days to ensure total AMPH clearance. During the MRI experiment, half of the rats in each experimental group received 4 mg/kg methylphenidate (MPH) i.p. (Sigma Aldrich, UK) dissolved in 0.9% saline in a volume of 0.3 ml to challenge the DA system. The other half of the animals received a saline challenge (same volume). This resulted in 4 experimental groups for the phMRI: pre-treated saline with saline challenge (SAL-SAL, N = 11), pre-treated saline with MPH challenge (SAL-MPH, N = 10), pre-treated AMPH with saline challenge (AMPH-SAL, N = 10) and pre-treated AMPH and challenge with MPH (AMPH-MPH, N = 11).

MRI experiments were performed using a 4.7 T Direct Drive Agilent (previously Varian, Palo Alto, CA) MRI system. Animals were placed in a linear radiofrequency coil with a volume with 72 mm inner diameter (m2m Imaging Corp., Cleveland OH, USA), which was used as a transmitter. The MR signal was received by four phased array coils (m2m Imaging Corp., Cleveland OH, USA) placed around the head of the animal. During the MRI scan, anaesthesia was maintained with 1.5–2.0% isoflurane and animals were ventilated in a 70:30 mixture of medical air and oxygen. Ventilation parameters, body temperature and heart rate were monitored throughout the scan.

For each animal, a T2 weighted anatomical image volume was acquired using a fast spin echo multi-slice sequence (fsems) with an echo train length of 8, matrix size = 256x256, FOV = 35x35 mm, 24 contiguous interleaved 1 mm coronal slices, 4 averages, 2 dummy scans, effective repetition time (TReff) = 5112 ms, and effective echo time (TEeff) = 60 ms. The time series were acquired using a gradient echo multi-slice (gems) sequence with 16 contiguous
interleaved 1 mm slices centred to the same position as the anatomical image with TR = 260 ms, TE = 14 ms, flip angle 40 deg, 2 averages, 2 dummy scans, FOV = 35x35 mm and matrix size of 128x96 (zero-fill to 128x128), covering the regions of interest. Fifty time points (acquisition time per time series volume was 50 s; total scan time of approximately 41 minutes) were acquired with an injection of the pharmacological challenge after acquisition of volume 12.

**MRI data analysis**

As a first step, the anatomical and time series data were converted to 4D Analyze format using ImageJ [14]. For image processing, the pixel dimensions were scaled by a factor of 10 to ensure compatibility with analysis algorithms designed for human data. This resulted in a voxel size of $2.73 \times 2.73 \times 10$ mm$^3$ for the time series data. Pre-processing included motion correction, which was applied by re-aligning the functional data to the first dynamic volume. In addition, anatomical and time series data were registered to a stereotactic rat brain template [15] using Statistical Parametric Mapping (SPM) software. Then, we co-registered the structural data to the rat template with 3, 6 and 12 degrees of freedom, respectively. Subsequently the data were normalized using a non-linear frequency cut-off of 15Hz. Next, all transformations were applied to the functional data [16]. Thereafter, the functional data were smoothed with a 3x3x7mm Gaussian kernel. Finally, brain extraction was obtained by multiplying a binary mask from the rat template with the functional data.

**ROI-based analysis.** We hypothesized the BOLD signal in certain DA-rich areas to be different between groups and therefore carried out ROI analyses in the CPu and NAcc. Mean time series per group per ROI were extracted from unsmoothed BOLD time series using a 3D digital reconstruction of a rat brain atlas [17] co-registered with the anatomical MRI template [15], using IDL-based software (Research Systems Inc., Boulder, Colorado). The anatomical definitions of the ROIs can be found in Gozzi et al. [18]. Statistical significance was assessed using SPSS version 20 (IBM, Chicago). We conducted a repeated-measures analysis with time (baseline (timepoint 1–12) and post-challenge (timepoint 15–35) as within-subject factor within each group to assess the change in BOLD signal compared to baseline. In addition, a repeated-measures analysis was done with time as within-subjects factor and group as between-subject factor to assess differences between groups. AMPH-MPH and SAL-MPH groups were compared with the two saline challenge groups combined (AMPH-SAL + SAL-SAL). In addition, the change in AMPH-MPH was compared to the SAL-MPH group to directly contrast the effect of pre-treatment on the response to MPH.

**Exploratory voxel-based analysis.** In addition to ROI-based analysis, exploratory whole brain analyses were conducted to explore the effects in regions downstream from DA projections. Image-based time series analysis was performed using FEAT v. 5.98, part of FSL [19]. First level analysis was conducted using a model based on exploratory data analysis to obtain the shape of the hemodynamic response according to Klomp et al. [20]. In brief, Stimulate software [21] was used to extract changes in signal intensity after the MPH challenge. All individual time courses were then averaged to obtain the basic shape of the first level model, which was normalized and smoothed before entering into the design matrix. The design matrix was composed of this model and its temporal derivative. Higher-level mixed effect analysis was carried out using ordinary least squares simple mixed effects as implemented in FSL FEAT to determine group differences. Z (Gaussianised T/F) statistic images were thresholded using clusters determined by $Z > 1.6$ and a (corrected) cluster significance threshold of $p = 0.05$ [22] (please see $Z > 1.9$ and $Z > 2.3$ thresholded maps in S1 Fig). AMPH-MPH and SAL-MPH groups were compared with the two saline challenge groups combined and were additionally tested against each other. The Paxinos and Watson rat brain atlas (1986) was used to identify
location of significantly activated brain regions. Using the average waveform from the current data set as time regressor might have introduced a bias in the results, even though the waveform was heavily smoothed. To assess whether this was the case, we also conducted the analysis with a boxcar waveform. In order to capture a possible time lag of the MPH effects we also analysed a delayed boxcar time course [23]. These results are shown in S2 Fig, and are comparable to the initial waveform used. It shows that the onset of the effect is rather rapid, even though delayed effects are also found.

**Immunocytochemistry for GFAP, DAT, DRD1 and DRD2 assessments**

Following MRI, a subset of animals (N = 15 AMPH pre-treated, N = 14 saline pre-treated) was perfused intracardially with saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (PB). To prevent pressure artefacts, brains were additionally post-fixed overnight in the skull at 4°C. The fixed brains were then saturated in a solution of 15% sucrose in PB (PB, 0.1M, pH 7.4) followed by 30% sucrose in PB for cryoprotection after which they were frozen and coronally sectioned in a one-in-ten series at 30 μm on a sledge microtome (Jung AG, Heidelberg, Germany). Immunocytochemistry was performed in the CPu and NAcc for: DAT (polyclonal rabbit anti-DAT 1:2000, Novus Biologicals NBP1-19013), DRD1 (monoclonal mouse anti-DA receptor D1α 1:2000, Millipore MAB5290), DRD2 (polyclonal rabbit anti-DA receptor D2α 1:400, Millipore AB5084P), and glial fibrillary acidic protein (GFAP, polyclonal rabbit anti-GFAP 1:2000, Dako Z0334) as described in detail in the S1 Supplementary Methods. Optical density was measured with the intensity function in *ImageJ* (Fiji, Image J) in one or multiple fixed-size regions. All sections were stained simultaneously and digitized with fixed settings. Light and background corrections were performed for all stainings except GFAP, due to the widespread distribution of GFAP.

**In vitro autoradiography for DAT and DRD1 assessments**

Animals (N = 12 AMPH pre-treated, N = 12 saline pre-treated) were sedated with isoflurane and euthanized by cervical dislocation and the brains were rapidly removed, snap frozen and stored at -80°C. Frontal brain sections (14 μm) were cut and DAT and DRD1 autoradiography was performed on the CPu and NAcc. [3H]WIN35428 (Perkin-Elmer®), France; specific radioactivity = 3.034 MBq/nmol; 5 concentrations from 0.55 to 15.0 nM) was used for the DAT binding experiments according to protocols described before by Hebert [24]. Non-specific binding was determined by incubation of adjacent brain slices in the presence of 10 μM nomifensine. For the DRD1 binding experiments, [3H]SCH-23,390 (Perkin-Elmer®), France; specific radioactivity = 3.119 MBq/nmol; 5 concentrations from 0.10 to 8.1 nM) was used and performed according to the Savasta protocol [25]. Non-specific binding was determined by incubation of adjacent brain slices in the same conditions and in the presence of 10 μM SKF38393. Brain sections were exposed to tritium-sensitive phosphor imaging plates (Perkin-Elmer®) before acquisition of images (Cyclone®, Perkin-Elmer®). Specific binding was calculated as the difference between total and non-specific binding and K_d and B_max values were derived from raw data using nonlinear fitting procedures (Prism®).

**Ex vivo storage phosphor imaging for DRD2/3 assessments**

Seven days following treatment, rats (N = 10 AMPH pre-treated, N = 10 saline pre-treated) were anesthetized with ketamine/xylazine mix followed by intravenous administration of approximately 50 MBq of the selective DRD2/3 tracer [123I]IBZM (GE Healthcare, Eindhoven, the Netherlands) into the tail vein. Ninety minutes later, rats were sacrificed using cardiac puncture under anaesthesia, and the brain was removed and frozen in nitrogen, sliced into
horizontal slices of 50 μm using a microtome cryostat at -21°C. Storage phosphor imaging was performed as described previously [26]. In brief, every fifth slice was mounted on a glass plate and exposed to phosphor plates (Fuji BAS-MS IP) for the duration of 12 hours, allowing the phosphor plates to absorb energy emitted by radioactive decay from $^{123}$IIBZM. The resulting luminescence emitted by the phosphor plates was scanned using a storage phosphor imager (GE Healthcare Typhoon FLA 7000) at a resolution of 25 μm using a 16-bit pixel depth, and analysed using ImageQuant TL Toolbox version 8.1. Regions of interest (ROIs) were the left and right CPu and the left and right NAcc, both DA-rich brain structures. The cerebellum was used to assess non-specific binding, as the cerebellum contains a negligible DRD2/3 density [27]. Specific dorsal CPu-to-cerebellum and NAcc-to-cerebellum ratios were obtained by dividing the average uptake per pixel of combined left and right CPu/NAcc parts by the average uptake per pixel of the cerebellum.

**Ex vivo HPLC for monoamine levels and metabolites**

Brains (N = 11 AMPH pre-treated, N = 12 saline pre-treated) were rapidly dissected on cold plates; CPu and frontal cortex (FC) were dissected, weighed and stored at -80°C for further analysis. The tissue samples were homogenized for 30 min in 100 μl of an extraction solution (pH = 3) constituted of the mobile phase supplemented with perchloric acid 0.1 M. The mobile phase (MD-3MA, Thermo Scientific, France) was pumped at 0.4 mL/min with an isocratic high-performance liquid chromatography (UltiMate 3000 system, Thermo Scientific Dionex, France). Electrochemical detection (Coulochem III, Thermo Scientific Dionex, France) enabled the detection of monoamines and their metabolites. Peak quantification was determined using the Chromeleon 7.2 software (Thermo Scientific Dionex, France) and their concentrations derived from external standard curves. Concentrations of each compound were computed as the average of the two extracted values per sample.

**Statistics**

Sample sizes were based on a previous study [13] with the same dosing regimen, taking into account possible drop-out due to complications of the treatment and/or MRI data quality. Power calculations showed that at least 10 rats per group were needed to detect an effect size of 1.8 (Cohen’s d). Rats were randomly assigned to either saline or AMPH treatment per cage and blinding was used for final statistical analyses. Data were analysed using two-sided independent t-tests or ANOVA to test for the effects of (i) repeated AMPH administration (ii) acute effect of MPH challenge. Data were assessed for normality using the Shapiro-Wilk test and equality of variance using Levene’s test. In case assumptions were violated, non-parametric tests were used. Corrections for multiple comparisons (NAcc and CPu) were conducted using the Benjamini-Hochberg procedure. Statistical analyses were performed using SPSS version 20.0 (IBM, Chicago) unless otherwise stated.

**Results**

**phMRI for DA-ergic functionality**

The acute MPH challenge induced a significant BOLD response at post-challenge relative to baseline in the AMPH-MPH group in the CPu ($F_{1,10} = 6.60, p = 0.03$; NAcc $F_{1,10} = 4.64, p = 0.06$; not significant after Benjamini-Hochberg correction), but not the SAL-MPH ($F_{1,9} = 1.20, p = 0.30$; NAcc $F_{1,9} = 1.60, p = 0.24$) and SAL challenge groups ($F_{1,20} = 1.09, p = 0.31$; NAcc $F_{1,20} = 0.53, p = 0.47$) (Fig 1). In addition, the change in BOLD response was higher in the AMPH-MPH group compared to the SAL groups combined (SAL-SAL + AMPH-AMPH-MPH).
SAL) in the CPu and NAcc (CPu $F_{1,30} = 7.95, p < 0.01; \text{NAcc} F_{1,30} = 4.40, p = 0.04$), but not in the SAL-MPH group compared to the SAL groups combined (CPu $F_{1,29} = 0.06, p = 0.82; \text{NAcc} F_{1,29} = 0.25, p = 0.62$). When comparing the AMPH-MPH and SAL-MPH group directly, the AMPH-MPH group showed a significantly larger BOLD response than the SAL-MPH group (CPu $F_{1,19} = 6.94, p = 0.02; \text{NAcc} F_{1,19} = 5.85, p = 0.03$). The whole brain analyses were in agreement with the ROI analysis, demonstrating that an acute MPH challenge significantly activated a number of clusters of voxels in the thalamus, hippocampus (HC), CPu and cortically in fronto-temporal areas in the AMPH-MPH group (Fig 2) when compared to the vehicle groups together. In addition, the SAL-MPH group also showed small increases in BOLD signal compared to baseline in thalamus and temporal cortex.

The acute MPH challenge only induced positive BOLD responses, but the extent of activation was much larger in the AMPH-MPH group than in the SAL-MPH group. In the SAL-MPH group, we observed small bilateral increases in activation in the thalamus and temporal cortex. In contrast, in the AMPH pre-treated group, a large number of regions showed a bilateral increase in BOLD signal intensity, including the thalamus, HC, CPu and cortically in
fronto-temporal areas. When the SAL-MPH and AMPH-MPH groups were compared directly, we found the strongest group differences in subcortical DA-rich structures, such as the striatum, thalamus and substantia nigra.

Immunocytochemistry for GFAP, DAT, DRD1 and DRD2 assessments
AMPH pre-treatment, compared to saline pre-treatment, resulted non-significant higher DRD1 immunoreactivity in the CPu (+14.1%, $t_{(27)} = 1.95$, $p = 0.06$) and significantly higher expression in the NAcc (+43.3%, $t_{(27)} = 2.14$, $p = 0.04$; not significant after Benjamini-Hochberg correction), as well as higher GFAP immunoreactivity in the CPu (+11.8%, $U = 59$, $p = 0.046$ not significant after Benjamini-Hochberg correction) (Fig 3 and S3 and S4 Figs). No differences were found in DRD1 or GFAP expression in other ROIs. AMPH pre-treatment did not significantly affect DRD2 or DAT immunoreactivity when compared to saline pre-treatment (S5 and S6 Figs).

In vitro autoradiography for DAT and DRD1 assessments
AMPH pre-treatment resulted in a significant 21–24% lower binding of DAT in the CPu ($t_{(18)} = 5.56$, $p<0.001$), NAcc ($t_{(21)} = 9.26$, $p<0.001$) compared to saline pre-treatment. DRD1 density was significantly lower in the NAcc (-7% $t_{(22)} = 2.83$, $p<0.01$) but not altered in the CPu ($t_{(22)} =$
0.78, p = 0.40). Mean and standard error of the mean (SEM) are displayed in Table 1 (S7 Fig illustrates the distribution of DAT and DRD1 binding sites).

**Ex vivo** storage phosphor imaging for DRD2/3 assessments

There was no significant difference in DRD2/3 receptor availability in the NAcc (\(t_{(18)} = 1.45, p = 0.16\)) or the CPu (\(t_{(18)} = 1.05, p = 0.31\)) between groups pre-treated with saline versus AMPH. Representative phosphor images from the AMPH and saline group are displayed in S8 Fig, as well as the mean and SEM.
Ex vivo HPLC for monoamine levels and metabolites

AMPH pre-treatment did not result in significantly different monoamine levels, except for increases in HVA levels in the CPu (+231%, \(p < 0.0001\)) (Table 2). No differences were found in the frontal cortex.

**Discussion**

We here used phMRI to investigate in rats the consequences of repeated AMPH administration, known to damage the DA synapse. We assessed whether a subsequent MPH challenge would allow to detect changes in DAT, DA receptor, DA levels and its metabolites, and therefore also validated these measures by analyzing them post-mortem. We demonstrate that AMPH pre-treatment increases the BOLD response to an acute MPH challenge in DA-inner-vated brain regions. The changes in BOLD response possibly reflect increased DA-ergic postsynaptic stimulation as supported by the higher HVA and reduced striatal DAT binding we found. However, based on autoradiography and ICC, contrasting results were found for DRD1 expression following AMPH treatment.

**Repeated AMPH treatment induces exacerbated BOLD response**

In accordance with Belcher et al. [13], our AMPH pre-treatment model induced reduction in DAT binding. In addition, the AMPH pre-treatment induced a higher BOLD response to an acute MPH challenge in subcortical DA areas. This exacerbated DA-ergic response to MPH may either be due to an increase in DA release and/or a reduction in its re-uptake or metabolism. This would result in the presence of more DA in the synaptic cleft and hence an increase

---

**Table 1. Effect of pre-treatment with AMPH on DAT and DRD1 binding (autoradiography).**

|          | DAT [3H]-WIN35428 \(B_{max}\) fmol/mg TE, mean ± SEM | DRD1 [3H]-SCH23390 \(B_{max}\) fmol/mg TE, mean ± SEM |
|----------|-------------------------------------------------------|-------------------------------------------------------|
|          | Saline | AMPH | Saline | AMPH |
| CPu      | 192 ± 5 | 151 ± 4*** | 361 ± 7 | 353 ± 8 |
| NAcc     | 407 ±9  | 308 ±5*** | 360 ±5  | 335 ±7** |

**p<0.01 *** p<0.001 (AMPH vs saline)

---

**Table 2. Effect of pre-treatment with AMPH on brain monoamines and metabolites.**

|       | NA MHPG | DA DOPAC | HVA | 5-HT | 5-HIAA |
|-------|---------|----------|-----|------|--------|
| CPU   | Saline  | 0.149 ± 0.022 | 2.162 ± 0.244 | 1.923 ± 0.199 | 1.295 ± 0.195 | 0.217 ± 0.014 | 0.305 ± 0.022 |
| AMPH  | 0.162 ± 0.030 | ND       | 2.001 ± 0.273 | 2.302 ± 0.268 | 4.293 ± 0.538*** | 0.227 ± 0.026 | 0.246 ± 0.028 |
| Cortex| Saline  | 3.390 ± 1.104 | 3.884 ± 0.580 | 0.043 ± 0.005 | 0.008 ± 0.001 | 0.378 ± 0.195 | 0.497 ± 0.026 | 0.369 ± 0.023 |
| AMPH  | 2.950 ± 0.261 | 3.212 ± 0.285 | 0.053 ± 0.018 | 0.006 ± 0.001 | 0.381 ± 0.050 | 0.478 ± 0.029 | 0.342 ± 0.019 |

Data (mean ± SEM) are concentrations (µg/g wet tissue) of monoamines (NA: Noradrenaline, DA: Dopamine, 5-HT: Serotonin) and metabolites (MHPG: 3-methoxy-4-hydroxyphenylglycol, DOPAC: 3,4-dihydroxyphenylacetic acid, HVA: homovanillic acid, 5-HIAA: 5-hydroxyindolacetic acid) in the striatum in saline and AMPH pre-treated rats, one week after the treatment.

* AMPH vs. Saline: \(p<0.0001\);
ND Not Detected.

---

do:10.1371/journal.pone.0172776.t001

do:10.1371/journal.pone.0172776.t002
in post-synaptic neurotransmission in AMPH pre-treated rats. Enhanced striatal DA release has been shown to induce both cortical and subcortical hemodynamic responses, reflecting its arousing and rewarding properties [28].

When animals are repeatedly exposed to psychostimulant drugs, the re-administration of the drug after a period of withdrawal results in an exaggerated DA release, which is consistent with the exacerbated BOLD response we observed following the MPH challenge. Additionally, the presently observed reduction in DAT binding could result in a decreased re-uptake and therefore elevated DA levels, possibly further augmenting DA neurotransmission [7]. Interestingly, these findings differ from clinical studies from our group, in which we found a blunted phMRI response and striatal DA release in regular AMPH users [29,30]. Yet, Boileau et al. (2006) found sensitization in humans who repeatedly received AMPH under similar conditions. This discrepancy between rodent and human studies is also observed for the effects of cocaine [31] and may be due to differences in timing and duration of administration (i.e. at an early stage of drug abuse vs. dependence, or after a wash-out period) as well as to effects of the environmental context, i.e. in relation to reward anticipation. Alternatively, the discrepancy between human and animal studies could possibly be explained by the use of anaesthesia. Although we cannot rule out the possibility that isoflurane has influenced our results (there has been some discussion on the effect of isoflurane on the DA system [32,33]), all groups received the same level of anaesthesia, so this is unlikely explains the large difference between our AMPH and saline groups. Previous studies had further suggested, that similar levels of anaesthesia, as in the present study, do not affect the sign and distribution of phMRI responses [34]. Future experiments in awake rats could advance the comparability between animal and human studies.

PhMRI studies reported in the literature have demonstrated that DA-ergic stimulants (including AMPH and MPH) elicit significant changes in the hemodynamic response of DA-innervated brain regions of healthy animals [8,10]. Yet in the saline pre-treated rats, we observed a small BOLD response as compared to AMPH-pretreated rats. It has been demonstrated previously that low doses of AMPH can induce a small hemodynamic response, probably due to a higher affinity for DRD2 (auto)receptors. These autoreceptors are expressed on the pre-synaptic terminal and their stimulation results in a lower DA release. Alternatively, higher doses of AMPH increase the phMRI signal more as a result of an increased binding of DA to DRD1 [35]. The current literature is somewhat equivocal, with both increases and decreases of the phMRI signal being reported [36–39] which may relate to methodological differences, such as the route and dose of MPH administration as well as the ventilation protocol used.

**What neurobiological changes drive the phMRI response?**

We here observed that AMPH treatment reduced DAT binding significantly in the CPu (-21%) and NAcc (-24%) as measured with $[^3]$H]WIN-35428 autoradiography. At first glance, this does not appear in concordance with our ICC findings where an no change in DAT was apparent. However, this can be explained by the fact that ICC measures the entire pool of DAT (i.e. intra- and extracellular, functional and not functional), whereas autoradiography assesses only the functional membrane DAT to which ligand can bind. Hence, the autoradiography data suggest that the active pool of DAT, and/or their activity, is reduced in AMPH-treated rats, corroborating our hypothesis of DAT-dependent changes in phMRI signal, whereas the entire pool (as measured with ICC) may have been increased as a compensatory response. Similarly, our results in DRD1 expression differ when measured with autoradiography and ICC. This suggests that although there might be an increase in the overall pool of DRD1
receptors, fewer receptors are functionally available (as supported by the autoradiography data), possibly due to an exaggerated DA neurotransmission. However, the reason for the increase in overall DRD1 levels remains elusive and requires further research. The concept of an AMPH-induced disruption of normal DA-ergic functioning is further supported by the increases in GFAP, a classical marker of astrogliosis, as has been reported before under similar, as well as degenerative conditions [40].

Furthermore, levels of the DA metabolite HVA were elevated in AMPH-pretreated rats while no differences were present in basal DA levels. Both DA and HVA were found to be increased following acute AMPH [41], likely as a result of reversed DA transport [40] or internalization of DAT [42], that would lead to an increase in the amount of DA in the synaptic cleft that can be metabolized. Moreover, the decreased DAT binding can result in less reuptake and more available DA to be metabolized [43]. In addition, acute AMPH has been shown to inhibit the activity of the enzyme monoamine oxidase (MAO) [40,44], initially resulting in reduced DA metabolism. One explanation could therefore be that, following one-week of washout and disinhibition of MAO, DA metabolism is still increased, resulting in higher HVA levels. Alternatively, our phMRI data suggest a slower breakdown of the released DA due to deficient DAT reuptake, which might again increase DA metabolism and thus result in higher HVA levels. Interestingly, no changes in HVA were found in the frontal cortex, a region with lower DAT expression than the CPu, where catechol-O-methyltransferase (COMT) and MAO are thought to play a larger role in the modulation of DA neurotransmission [44]. This suggests that AMPH-induced DAT deficiency has a larger impact on changes in DA metabolism in the CPu than in the frontal cortex.

**Methodological considerations**

This experiment used BOLD contrast to visualize hemodynamic changes, instead of contrast-enhanced cerebral blood volume (CBV) phMRI studies. Although CBV-weighted imaging might provide a higher sensitivity, BOLD contrast is more often used in the clinical research setting and our findings can therefore be more easily translated to the human situation. Systemically administered challenges can induce systemic changes to various physiological parameters that can hamper interpretation of the BOLD response. For these reasons, blood pressure and pCO$_2$ levels were carefully monitored in our study while previous studies have shown that systemic changes as a result of i.v. administration with AMPH did not affect phMRI results [8]. We used i.p. administration of MPH, which will induce less systemic changes and these are therefore considered negligible for the interpretation of our results. Although we cannot exclude some bias in the waveform applied for the whole-brain analyses, using box car regressors provided us with similar results, therefore making the possibility of bias less likely.

Finally, it is important to note that psychostimulants such as AMPH and MPH not only affect the DA system, but also act on the noradrenergic (NA) system and can have downstream effects on other neurotransmitter systems. Especially in cortical areas, where NAergic neurons are involved in regulating DA [45], MPH-induced changes may, at least in theory, involve mixed DA-ergic and NAergic activation. Although we did not find any changes in NA (metabolites) in our AMPH treated rats, we cannot completely exclude this further research into this will be of interest.

**Conclusions**

We report that AMPH pre-treatment, which is known to induce neurotoxic changes in the DA synapse, induced an exaggerated phMRI response to a subsequent DAergic challenge in
rats. Our validation data indicate that the phMRI signal changes are likely explained by increases in DA neurotransmission. Consistent with literature, we demonstrate that repeated AMPH reduced striatal DAT and increased HVA levels. This supports that phMRI is sensitive enough to measure complex alterations in the DA system. This ability to assess subtle synaptic changes is promising for both preclinical studies of DA-ergic drug discovery and monitoring as well as for future clinical studies where phMRI can be used to investigate DA abnormalities, e.g. in various neuropsychiatric disorders, in a non-invasive way.

Supporting information

S1 Supplementary Methods.

S1 Supplementary Data.

S1 Fig. Additional whole brain analyses with more stringent thresholds. The analyses were exactly the same as reported in the results section, but with higher z-thresholding. The top three rows are thresholded at z>1.9 and the bottom three rows are thresholded at z>2.3.

S2 Fig. Additional whole brain analyses with boxcar regressors. Left) boxcar regressor with immediate response following MPH administration (EARLY); right) boxcar regressor with lagged response following MPH administration (after 29 volumes) (LATE); The images are thresholded at z>1.6.

S3 Fig. DRD1 expression in the CPu and NAcc in representative rats for each group.

S4 Fig. GFAP expression in the CPu and NAcc in representative rats for each group.

S5 Fig. DAT expression in the CPu and NAcc in representative rats for each group.

S6 Fig. DRD2 expression in the CPu and NAcc in representative rats for each group.

S7 Fig. Representative illustration of the cerebral distribution of DAT (B) and DRD1 (C) binding sites at the level of the CPu and NAcc (A; Bregma + 1.60 mm) in a control rat.

S8 Fig. Storage phosphor imaging for DRD2/3 assessments. a) Examples of regions of interest for CPu (A), NAcc (B) and cerebellum (C), b) DRD2/3 binding potential in the CPu and NAcc in AMPH and saline pre-treated rats (mean+SEM).

Acknowledgments

The authors are grateful to Sylvie Chalon, Sophie Corvaisier, Virgile Delaunay, Marion Hébert, François-Xavier Lepelletier and Marion Vanneste for expert technical help and advice.
**Author Contributions**

Conceptualization: AS FD WG PL JR JB.

Formal analysis: AS PH WG AG VB LG.

Funding acquisition: LR PL FD WG.

Methodology: AS JT MW VB PH GM KB JK TF MB ED LG AG.

Project administration: AS.

Writing – original draft: AS LR PL.

**References**

1. McCann UD, Ricaurte GA. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev. 2004; 27: 821–826. doi: 10.1016/j.neubiorev.2003.11.003 PMID: 15019431

2. Gibb J, Hanson G, Johnson M. Neurochemical mechanisms of toxicity. Amphetamine and its analogs. 1994. pp. 269–295.

3. Advokat C. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. J Atten Disord. 2007; 11: 8–16. doi: 10.1177/1087054706295605 PMID: 17606768

4. Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry. Nature Publishing Group; 2009; 14: 123–42.

5. Ricaurte GA, Mechan AO, Yuan J, Hatzidimitriou G, Xie T, Mayne AH, et al. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J Pharmacol Exp Ther. 2005; 315: 91–98. doi: 10.1124/jpet.105.087916 PMID: 16014752

6. Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, et al. Modeling Sensitization to Stimulants in Humans. Arch Gen Psychiatry. American Medical Association; 2006; 63: 1386–1395.

7. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like stimulants. Brain Res Rev. 1997; 25: 192–216. PMID: 9403138

8. Choi JK, Chen Y, Hamel E, Jenkins BG. Brain hemodynamic changes mediated by dopamine receptors: role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. Neuroimage. Elsevier; 2006; 30: 700–712.

9. Jenkins BG, Sanchez-Pernaute R, Brownell AL, Chen YCI, Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J Neurosci. 2004; 24: 9553–9560. doi: 10.1523/JNEUROSCI.1558-04.2004 PMID: 15509742

10. Gozzi A, Tessari M, Dacone L, Agosta F, Lepore S, Lanzi A, et al. Neuroimaging evidence of altered fronto-cortical and striatal function after prolonged cocaine self-administration in the rat. Neuropsychopharmacology. Nature Publishing Group; 2011; 36: 2431–2440.

11. Squillace M, Dodero L, Federici M, Migliarini S, Errico F, Napolitano F, et al. Dysfunctional dopaminergic neurotransmission in asocial BTBR mice. Transl Psychiatry. Nature Publishing Group; 2014; 4: e427.

12. Belcher AM, O’Dell SJ, Marshall JF. Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine-or d-amphetamine-induced neurotoxicity. Neuropsychopharmacology. Nature Publishing Group; 2005; 30: 2026–2034.

13. Abramoff MD, Magalhães PJ, Ram Sj. Image processing with ImageJ [Internet]. Biophotonics international. http://www.photonics.com/; 2004. pp. 36–42. http://dspace.library.uu.nl/handle/1874/204900

14. Schwarz AJ, Danckaert A, Reese T, Gozzi A, Paxinos G, Watson C, et al. A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: application to pharmacological MRI. Neuroimage. 2006; 32: 538–50. doi: 10.1016/j.neuroimage.2006.04.214 PMID: 16784876

15. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007; 38: 95–113. doi: 10.1016/j.neuroimage.2007.07.007 PMID: 17761438

16. Paxinos G, Watson C. The rat brain in stereotactic coordinates. 5th ed. Berlin: Elsevier; 1986.
18. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology. American College of Neuropsychopharmacology; 2008; 33: 1690–703.

19. Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. Fsl. Neuroimage. 2012; 62: 782–90. doi: 10.1016/j.neuroimage.2011.09.015 PMID: 21979382

20. Klomp A, Tremoleda JL, Wylezinska M, Nederveen AJ, Feenstra M, Gsell W, et al. Lasting effects of chronic fluoxetine treatment on the late developing rat brain: Age-dependent changes in the serotoninergic neurotransmitter system assessed by pharmacological MRI. Neuroimage. 2011;

21. Strupp JP. Stimulate: A GUI based IMRI analysis software package. 1996. p. S607.

22. Worsley KJ. Statistical analysis of activation images. Functional MRI: An introduction to methods. 2001. pp. 251–270.

23. McKie S, Del-Ben C, Elliott R, Williams S, del Vai N, Anderson I, et al. Neuronal effects of acute citalopram detected by pharmacoMR I. Psychopharmacology (Berl). 2005; 180: 680–686.

24. Hebert MA, Larson GA, Zahniser NR, Gerhardt GA. Age-Related Reductions in $[^3]H$WIN 35,428 Binding to the Dopamine Transporter in Nigrostriatal and Mesolimbic Brain Regions of the Fischer 344 Rat. J Pharmacol Exp Ther. 1999; 288: 1334–1339. Available: http://jpet.aspetjournals.org/content/288/3/1334.short PMID: 10027875

25. Savasta M, Dubois A, Scatton B. Autoradiographic localization of D1 dopamine receptors in the rat brain with $[^3]H$SCH 23390. Brain Res. 1986; 375: 291–301. Available: http://www.ncbi.nlm.nih.gov/pubmed/2942221 PMID: 2942221

26. Schouw MLJ, Caan MWA, Geurts HM, Schmand B, Booij J, Nederveen AJ. Monoaminergic dysfunction in recreational users of dexamphetamine. Eur Neuropsychopharmacol. 2013; 23: 1491–1502. doi: 10.1016/j.euroneuro.2013.01.005 PMID: 23415394

27. Schanz A, Gozzi A, Reese T, Heidbreder CA, Bifone A. Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A. Magn Reson Imaging. Elsevier; 2007; 25: 811–820.

28. Ren J, Xu H, Choi J-K, Jenkins BG, Chen YI. Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses. Synapse. 2009; 63: 764–72. doi: 10.1002/syn.20659 PMID: 19484725

29. Chen Y, Choi J-K, Xu H, Ren J, Anderssen SL, Jenkins BG. Pharmacologic neuroimaging of the ontogeny of dopamine receptor function. Dev Neurosci. 2010; 32: 125–38. doi: 10.1159/000286215 PMID: 20623024

30. Easton N, Marshall FH, Marsden CA, Fone KCF. Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast. Neuropharmacology. 2009; 57: 653–64. doi: 10.1016/j.neuropharm.2009.08.018 PMID: 19733553

31. Canese R, Adriani W, Marco EM, De Pasquale F, Lorenzini P, De Luca N, et al. Peculiar response to methylphenidate in adolescent compared to adult rats: A phMRI study. Psychopharmacology (Berl). 2009; 203: 143–153.
39. Hewitt KN, Shah YB, Prior MJW, Morris PG, Hollis CP, Fone KCF, et al. Behavioural and pharmacological magnetic resonance imaging assessment of the effects of methylphenidate in a potential new rat model of attention deficit hyperactivity disorder. Psychopharmacology (Berl). 2005; 180: 716–723.

40. Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci. 1998; 18: 4861–4869. PMID: 9634552

41. Bredeloux P, Dubuc I, Costentin J. Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br J Pharmacol. 2007; 150: 711–719. doi: 10.1038/sj.bjp.0707151 PMID: 17293887

42. Saunders C, Ferrer J V, Shi L, Chen J, Merrill G, Lamb ME, et al. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A. 2000; 97: 6650–6655. doi: 10.1073/pnas.110035297 PMID: 10823899

43. Gulley JM, Zahniser NR. Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands. Eur J Pharmacol. 2003; 479: 139–52. Available: http://www.ncbi.nlm.nih.gov/pubmed/14612145 PMID: 14612145

44. Huotari M, García-Horsman JA, Karayiorgou M, Gogos J a., Männistö PT. d-Amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl). 2004; 172: 1–10.

45. Stahl SM. Dopamine Is a Hitchhiker in Frontal Cortex: Norepinephrine Transporters Regulate Dopamine. J Clin Psychiatry. Physicians Postgraduate Press, Inc.; 2003; 64: 4–5. Available: http://www.psychiatrist.com/JCP/article/Pages/2003/v64n01/v64n0101.aspx